We’re looking to make Beyfortus available to protect infants in the US and Europe ahead of the 2023 RSV season. Next slide please. The continued growth of Farxiga is the result of a decade long development plan to broaden its use from diabetes to chronic kidney disease and heart failure patients. Our pioneering research has led to Farxiga becoming the leading medicine in its class, bringing its mortality benefits from news of patients globally. We see further opportunities to come for the [indiscernible] molecule and other combination therapies, giving us the potential to address additional unmet needs among cardiorenal patients and other indications. Our Farxiga combinations remain on track which plans for Phase III decisions later this year.
With that, please advance to the next slide, and I wind over to Mene.
Mene Pangalos: Thanks, Ruud. This slide and everyone —- we are on the right slide. This slide outlines our participation at recent medical congresses where we showcased data for tozorakimab, our anti-IL33 monoclonal antibody. We also highlighted the importance of real-world data and patient outcomes across R&I and CVRM. Firstly, the American Thoracic Society Congress, lung tissue samples taken from patients with COVID-19 were stained and analyzed. And the images I am showing you here show localization of higher levels of IL-33 in the airway tissues providing further sign rational for targeting IL-33 in severe viral infections in our Phase III TLIA trial. Also at ATS, real-world data highlighted the importance of prompt intervention with BREZTRI, initiating treatment within 30 days following a moderate or severe COPD exacerbation decrease the risk of future exacerbations by 24% versus delaying treatment by six months and by 34% versus the delaying treatment six months to one year.
At the European Renal Association, we presented real-world evidence underscoring the importance of early diagnosis of CKD. Multinational study, REVEAL CKD, demonstrated that 85% to 95% of Stage 3 CKD remains undiagnosed. Data also showed that delaying diagnosis by just one year, resulted in an increased risk of deterioration, kidney transplant or long-term dialysis treatment. The ZORA study supported continued concomitant use of potassium binders in RAASi patients who experience hyperkalemia. In response, we’ve already seen updates to a number of CKD and heart failure treatment guidelines. Please advance to the next slide. I wanted to also take the opportunity to highlight the broad modalities and technologies we now have in our armory. Over the past decade, we have built these capabilities to provide our scientists with access to the most relevant biological pathways and targets.
And as you can see, these are starting to mature and gain momentum. We have a portfolio of antisense oligonucleotides across amyloidosis, NASH and CKD in clinical development. These are precision medicine approaches that target the underlying biology of the disease in specific patient subpopulations. For example, our PNPLA3 AZD2693 dosed in Phase IIb in NASH this quarter bellowing promising Phase I data, which showed a steatosis reduction and positive gene knockdown at 12 weeks. In advanced biologics, AZD8630 is a human anti-TSLP fragment antibody formulated for inhaled dry powder delivery. AZD8630 is currently in Phase I in patients with poly-controlled asthma with data expected later this year. Also later this year, we’re expecting dates from our NGF TNA bispecific monoclonal antibody currently in Phase II for the treatment of OA pain and neuropathic pain.
In autoimmune disease, we recently announced a collaboration with Quell Therapeutics to develop engineered Treg-based cell therapies for autoimmune combined with our own expertise in this space, we can accelerate the development of this novel therapeutic approach with the potential to be curative in type 1 diabetes and in inflammatory bowel disease. With the acquisition of Alexion, our gene therapy ambitions have also accelerated significantly, utilizing our proprietary CRISPR gene editing platform to address challenging rare diseases, where together building an approach, we hope we will offer better safety margins. We’re also working with Alexion teams to optimize the therapeutic window through the use of novel tissue-directed capsids and tissue-specific promoters.
